First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Conditions
Breast Cancer · Solid Tumors, Adult
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Ellison Clinic at Saint John's, Los Angeles, California, United States
Contact: Principal Investigator (Reva Basho)UCSF Medical Center at Mission Bay, San Francisco, California, United States
Contact: Principal Investigator (Varun Monga)University of Colorado Cancer Center, Aurora, Colorado, United States
Contact: Principal Investigator (Anthony Elias)Yale-New Haven Hospital, New Haven, Connecticut, United States
Florida Cancer Specialists ORLANDO/DDU, Lake Mary, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Principal Investigator (Aixa Soyano)Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
Contact: Principal Investigator (Manali Bhave)University of Iowa, Iowa City, Iowa, United States
Contact: Principal Investigator (Mark Burkard)Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States
Contact: Principal Investigator (Shou-Ching Tang)Massachusetts General Hospital, Boston, Massachusetts, United States
Contact: Principal Investigator (Dejan Juric)Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Antonio Giordano)Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
START Midwest, Grand Rapids, Michigan, United States
Contact: Principal Investigator (Manish Sharma)Saint Luke's Cancer Institute, Kansas City, Missouri, United States
Contact: Principal Investigator (Timothy Pluard)Washington University, St Louis, Missouri, United States
Contact: Principal Investigator (Cynthia Ma)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Komal Jhaveri)UH Cleveland Medical Center, Cleveland, Ohio, United States
Contact: Principal Investigator (Alberto Montero)Stefanie Spielman Comprehensive Breast Center, Columbus, Ohio, United States
Contact: Principal Investigator (Robert Wesolowski)Providence Cancer Institute Franz Clinic, Portland, Oregon, United States
Contact: Principal Investigator (David Page)The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee, United States
Contact: Principal Investigator (Gregory Vidal)Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact: Principal Investigator (SMO Sarah Cannon Research Inst.)Mary Crowley Cancer Research Center, Dallas, Texas, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Contact: Principal Investigator (Joyce O'Shaughnessy)University of Texas Southwestern, Dallas, Texas, United States
Contact: Principal Investigator (Nisha Unni)University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Jordi Rodon Ahnert)START San Antonio, San Antonio, Texas, United States
Contact: Principal Investigator (Amita Patnaik)START Mountain Region, West Valley City, Utah, United States
Contact: Principal Investigator (William McKean)USO-Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Contact: Principal Investigator (Alexander Spira)Institut Jules Bordet, Anderlecht, Belgium
Contact: Principal Investigator (Philippe Aftimos)UZ Leuven, Leuven, Belgium
Contact: Principal Investigator (Patrick Neven)Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, France
Contact: Principal Investigator (Maxime Brunet)Centre Leon Berard, Lyon, France
Contact: Principal Investigator (Isabelle Ray-Coquard)Institut Paoli-Calmettes, Marseille, France
Contact: Principal Investigator (Cecile Vicier)Centre Antoine-Lacassagne, Nice, France
Contact: Principal Investigator (Philippe Follana)Institut Claudius Regaud, Toulouse, France
Contact: Principal Investigator (Eleonora De Maio)Gustave Roussy, Villejuif, France
Contact: Principal Investigator (Barbara Pistilli)Universitätsklinikum Erlangen, Erlangen, Germany
Contact: Principal Investigator (Peter Fasching)Mater Misericordiae Hospital, Dublin, Ireland
Contact: Principal Investigator (Austin Duffy)Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Contact: Principal Investigator (Giulia Gallizzi)Spedali Civili di Brescia, Brescia, Italy
Contact: Principal Investigator (Rebecca Pedersini)Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Contact: Principal Investigator (Giulia Bianchi)Istituto Europeo di Oncologia, Milan, Italy
Contact: Principal Investigator (Giuseppe Curigliano)Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
Contact: Principal Investigator (Marina Cazzaniga)Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara, Pisa, Italy
Contact: Principal Investigator (Carmelo Bengala)Ospedale Santa Maria delle Croci, Ravenna, Italy
Contact: Principal Investigator (Stefano Tamberi)Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy
Contact: Principal Investigator (Gennaro Daniele)Centro Ricerche Cliniche di Verona s.r.l., Verona, Italy
Contact: Principal Investigator (Andrea Zivi)National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
Contact: Principal Investigator (Eriko Tokunaga)Kansai Medical University Hospital, Hirakata, Japan
Contact: Principal Investigator (Toshio Shimizu)The Cancer Institute Hospital of JFCR, Kōtō City, Japan
Contact: Principal Investigator (Yukinori Ozaki)Kyoto University Hospital, Kyoto, Japan
Contact: Principal Investigator (TAKAKO NAKAJIMA)Netherlands Cancer Institute, Amsterdam, Netherlands
Contact: Principal Investigator (Marloes G.J. van Dongen)Erasmus MC, Rotterdam, Netherlands
Contact: Principal Investigator (Agnes Jager)Hospital Quiron Barcelona, Barcelona, Spain
Contact: Principal Investigator (Guzman Alonso Casal)South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos, Barcelona, Spain
Contact: Principal Investigator (Tatiana Hernandez Guerrero)Instituto Oncologico Dr Rosell (IOR), Barcelona, Spain
Contact: Principal Investigator (Jose Manuel Perez Garcia)Hospital Universitari Vall d'Hebron, Barcelona, Spain
Contact: Principal Investigator (Cristina Saura Manich)Hospital San Pedro, Logroño, Spain
Contact: Principal Investigator (Maria Jose de Miguel Luken)MD Anderson Cancer Center, Madrid, Spain
Contact: Principal Investigator (Maria Calvo Plaza)Hospital Clinico San Carlos, Madrid, Spain
Contact: Principal Investigator (Jorge Bartolome Arcilla)Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
Contact: Principal Investigator (Bernard Doger de Speville Uribe)Hospital Universitario HM Sanchinarro, Madrid, Spain
Contact: Principal Investigator (Juan Jose Soto)Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón, Spain
Contact: Principal Investigator (Valentina Boni)Hospital Universitari Sant Joan de Reus, Reus, Spain
Contact: Principal Investigator (Kepa Amillano Parraga)Hospital Universitario Virgen Macarena, Seville, Spain
Contact: Principal Investigator (Luis de la Cruz Merino)
Study leads
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company